JNJ Is Down 8%. What History Says About This 54-Day Drop.
Johnson & Johnson Just Exited Its Worst Sell-Off in Months. What History Says.
Johnson & Johnson (JNJ) has officially transitioned from the yellow zone to the green zone as of May 18, 2026. Our data shows the current drawdown has moderated to -7.9% from the all-time high of $248.56. This movement indicates a significant reduction in risk levels according to our proprietary tracking metrics.
Drawdown Severity Score™
Down 8% over 56 days. This is within the normal range for this asset.
1.78
Price
$229.32
All-Time High
$248.56
Drawdown
-7.7%
Duration
56 days
Current Drawdown Severity and Zone Transition
The Drawdown Severity Score™ for Johnson & Johnson (JNJ) currently sits at 1.8. This score classifies the stock in the "Slightly Elevated" or green zone, a notable improvement from its recent position in the yellow zone. The stock has spent 54 days in this current drawdown cycle, moving toward a potential recovery as the price reached $228.92 as of May 18, 2026.
We measure these transitions to provide context on how a stock is performing relative to its own historical volatility. Moving from the yellow zone to the green zone suggests that the selling pressure has decelerated. Our data indicates that while the stock remains below its peak, the intensity of the decline has fallen below the thresholds that typically signal heightened risk for this specific asset.
Tracking the 54-Day Decline
The current 54-day duration of this drawdown exceeds the historical average for this asset. Our data shows that Johnson & Johnson (JNJ) typically experiences drawdown durations averaging 42 days. At 54 days, the current cycle is roughly 28% longer than the historical mean, representing a more persistent period of price depression than the stock usually encounters.
JNJ Drawdown History
Percentage below all-time high over time
Now
-7.7%
The depth of the current -7.9% drawdown also exceeds the average maximum drawdown of -3.6% recorded across 329 historical drawdown events. While the Drawdown Severity Score™ has improved, the stock still has a 7.9% gap to close before reaching its previous all-time high. We track these metrics to identify when a stock's behavior deviates from its long-term historical norms.
Historical Drawdown Context and Comparisons
To understand the current -7.9% decline, we must look at the 329 historical drawdown events we have recorded for Johnson & Johnson (JNJ). The stock has a history of relatively shallow pullbacks, as evidenced by the -3.6% average. The current move to a 1.8 Drawdown Severity Score™ places this event in the upper tier of its typical price fluctuations.
In the most extreme cases, our data shows that Johnson & Johnson (JNJ) has dropped 30% or more exactly 5 times in its history. When the stock hits those extreme severity levels, the average duration of the comparable drops is 807 days. While the current drawdown of -7.9% is far from those historic lows, the Drawdown Severity Score™ provides a standardized way to compare today's price action against those 5 major historical events.
What History Says
JNJ has dropped 30%+ from its high 5 times in its tracked history.
Occurrences
5
Avg Duration
807
days
Data-Driven Analysis Framework
Our analysis of Johnson & Johnson (JNJ) relies exclusively on verified price, drawdown, severity, and duration data. We do not incorporate fundamental earnings data, analyst price targets, or external market narratives into this assessment. This report is based on the mathematical relationship between the current price of $228.92 and the historical peak of $248.56 as of May 18, 2026.
By focusing on the Drawdown Severity Score™, we provide a perspective based on how the stock has actually behaved over hundreds of cycles. This data-only approach allows investors to see where the current 54-day decline fits within the broader history of the stock without the influence of subjective market commentary.
Monitoring Severity Thresholds
The transition to the green zone is a specific data milestone, but it does not mean the drawdown is over. We continue to monitor the Drawdown Severity Score™ for any reversal back into the yellow zone. A score increase would indicate that the price is once again deviating negatively from its historical recovery patterns.
For Johnson & Johnson (JNJ), the path to a full recovery requires a return to the $248.56 level. We will continue to track the duration of this event, which currently stands at 54 days, against the 807-day average seen in more severe historical declines. Investors can use these specific price levels and severity scores to contextualize the stock's current risk profile within its historical framework.
Track JNJ's Drawdown Severity Score™
Set a custom alert and get notified when JNJ crosses into a new severity zone.
Get Started FreeGet the weekly drawdown digest
A weekly summary of fresh drawdown analysis, market severity changes, and watchlist setup ideas. No per-article blasts.
Frequently Asked Questions
How far has JNJ fallen from its all-time high?
Johnson & Johnson has fallen 7.9% from its all-time high of $248. The stock reached a price of $228.92 as of May 18, 2026, during this current 54-day cycle. This decline is significantly deeper than the stock's historical average maximum drawdown of 3.6%.
What is JNJ's drawdown?
The current Drawdown Severity Score for JNJ is 1.8, which places the stock in the green zone. This classification indicates that the risk level is slightly elevated but improving from previous weeks. Historically, this transition suggests that the intense selling pressure the stock recently faced has begun to decelerate.
How long has JNJ been in a drawdown?
JNJ has been in its current drawdown cycle for 54 days as of the latest data. This duration is notably longer than the company's historical average drawdown of 42 days. The current period of price depression has lasted roughly 28% longer than what the stock typically encounters during a pullback.
Disclaimer: DrawdownAlerts provides historical data analysis, not financial advice. Past performance does not guarantee future results. Severity scores are analytical tools, not buy/sell signals. Always do your own research before making investment decisions.